Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload in people with thalassaemia
Please note that following on from information provided to NICE by the company in June 2011, the appraisal of Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload [ID350] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 350
- Referral date:
- 01 July 2010
- Topic area
- Blood and immune system, Endocrine, nutritional and metabolic
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- Shalu Kanal
- Executive Lead:
- Peter Littlejohns
- Project manager:
- Jeremy Powell
- Technical Lead:
- Raisa Sidhu
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in June 2011, the appraisal of Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload [ID350] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
For further information on our processes and methods, please see our CHTE processes and methods manual